ANI Pharmaceuticals (NASDAQ:ANIP) Issues Quarterly Earnings Results

ANI Pharmaceuticals (NASDAQ:ANIP) announced its earnings results on Thursday. The specialty pharmaceutical company reported $2.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.18 by $0.52, FiscalAI reports. The business had revenue of $290.78 million during the quarter, compared to analyst estimates of $280.59 million. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%. The company’s revenue for the quarter was up 27.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.04 earnings per share.

Here are the key takeaways from ANI Pharmaceuticals’ conference call:

• ANI reported third-quarter revenue of $290.8 million, up 28% year over year, and adjusted EBITDA of $83.3 million, up 40%; adjusted diluted EPS rose to $2.70. Generics revenue increased 11% to $104.5 million, while ILUVIEN revenue grew 34% to $22.3 million.
• Cortrophin Gel revenue was $138.7 million, below expectations, as specialty-pharmacy capacity constraints and slower onboarding at new gout prescribers delayed conversion of cases to patients on therapy. ANI cut 2026 Cortrophin guidance to $480 million–$500 million from $520 million–$540 million, while citing strong demand and steps to improve fulfillment.
• ANI updated 2026 total revenue guidance to $1.085 billion–$1.125 billion and raised adjusted EBITDA guidance to $290 million–$300 million and adjusted EPS guidance to $9.37–$9.71; ILUVIEN guidance also increased to $80 million–$85 million. The company said strong profitability and favorable product mix support the higher earnings outlook.
• ANI announced an all-cash offer for Egetis Therapeutics valuing its equity at $560 million, adding EMCITATE, the first approved treatment for MCT8 deficiency, to its rare-disease portfolio. ANI sees peak annual sales potential above $300 million and expects to leverage its commercial infrastructure, though the deal is expected to dilute adjusted EPS in year one and raise pro forma net leverage to about 2.7x.

ANI Pharmaceuticals Stock Performance

ANIP opened at $67.41 on Friday. The business has a fifty day simple moving average of $72.52 and a 200 day simple moving average of $77.32. ANI Pharmaceuticals has a 1 year low of $67.14 and a 1 year high of $95.45. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.91 and a quick ratio of 2.41. The company has a market capitalization of $1.55 billion, a PE ratio of 13.43, a price-to-earnings-growth ratio of 2.28 and a beta of 0.45.

Analyst Upgrades and Downgrades

ANIP has been the subject of several recent research reports. Oppenheimer assumed coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, September 23rd. They set a “market perform” rating and a $85.00 price target for the company. Guggenheim increased their target price on ANI Pharmaceuticals from $119.00 to $121.00 and gave the stock a “buy” rating in a report on Friday. Weiss Ratings lowered shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Canaccord Genuity Group reduced their target price on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a report on Monday, August 10th. Finally, Wall Street Zen cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Three research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $100.00.

Insider Activity at ANI Pharmaceuticals

In other news, SVP Ori Gutwerg sold 3,162 shares of ANI Pharmaceuticals stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $77.00, for a total value of $243,474.00. Following the completion of the transaction, the senior vice president owned 75,534 shares in the company, valued at $5,816,118. This trade represents a 4.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jeanne Thoma sold 1,000 shares of the company’s stock in a transaction on Friday, September 11th. The shares were sold at an average price of $71.53, for a total transaction of $71,530.00. Following the sale, the director owned 26,762 shares of the company’s stock, valued at $1,914,285.86. This represents a 3.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 30,412 shares of company stock valued at $2,220,970 over the last three months. Insiders own 8.10% of the company’s stock.

ANI Pharmaceuticals News Summary

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: ANI reported Q3 2026 adjusted earnings of $2.70 per share, above the roughly $2.18 analyst consensus, and revenue of $290.78 million versus estimates of $280.59 million. Revenue grew 27.6% year over year, supporting the company’s growth outlook. ANI Q3 financial results
• Positive Sentiment: Guggenheim raised its price target from $119 to $121 and maintained a Buy rating, signaling continued analyst confidence in ANIP’s prospects. Guggenheim ratings
• Neutral Sentiment: ANI announced a recommended offer to acquire Swedish biotech Egetis Therapeutics for SEK 5.6 billion (about $560 million). The deal would expand ANI’s rare-disease business, but its financial impact and execution will matter to investors. ANI offer for Egetis
• Negative Sentiment: The sizable acquisition may raise concerns about funding, integration, and the risks of expanding into a new business, potentially weighing on shares despite the earnings beat. ANI offer to acquire Egetis

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with limited competition, complex formulations and specialized manufacturing requirements, serving therapeutic areas that include endocrinology, immunology, ophthalmology, dermatology and central nervous system disorders.

ANI’s portfolio includes branded products and generic medicines, as well as treatments for rare diseases.